Butylphthalide is a commonly used drug for the treatment of ischemic cerebrovascular disease and is available in both oral and injectable sizes. Patients should preferably take the drug by injection within 2 days of onset and switch to oral dosing after 2 weeks. The dosing method is usually two capsules per dose, three times a day for 20 days. Butylphthalein is a new class of drugs developed by the state, which is the active ingredient extracted from watercress into the drug, the main role is to protect the mitochondrial function, increase the oxygen supply of mitochondria, scavenging free radicals, can significantly reduce the local brain tissue ischemic area, reduce brain edema, reduce brain cell death, increase brain microcirculation, etc.. In addition, it can partially inhibit thrombus formation and promote the recovery of neurological function of brain cells, etc. It is recommended to be administered within 2 days of the onset of the disease, and its effect is better against the ischemic hemispheric zone which takes 5-7 days to restore blood supply. Adverse effects of butylphthalide are rare, but occasionally there may be elevated transaminases or gastrointestinal discomfort. Therefore, patients’ liver and kidney function should be monitored after taking the drug.